Fragile X Treatment Pipeline: Current and Emerging Clinical Trials

June 16, 2026

Watch FRAXA’s Fragile X clinical trials webinar featuring leading researchers discussing current studies, emerging treatments, trial eligibility, and the future of the Fragile X treatment pipeline.

Read More »
Close-up illustration of a neuron and synapses symbolizing brain signaling and BK channel activity in Fragile X syndrome

Opening the Gate: BK Channel Modulation as a Promising Treatment Strategy for Fragile X Syndrome

April 2, 2026

Fragile X syndrome research is opening the door to BK channel therapies that may calm hyperexcitable brain circuits and improve key symptoms.

Read More »
Craig Erickson, MD (left) and Stella Sarraf, PhD (right) on a video call for the Spinogenix SPG601 Fragile X clinical trial.

Spinogenix and FRAXA Advance SPG601 Into Phase 2b Trial for Fragile X Syndrome

March 2, 2026

Spinogenix and FRAXA are supporting a Phase 2b clinical trial of SPG601 in Fragile X syndrome, building on Phase 2 signals and FDA designations.

Read More »
Two people holding hands, symbolizing a research partnership.

Nospharma Announces Partnership with FRAXA to Test NOS-01 in Pre-Clinical Models of Fragile X

February 4, 2026

NOS-01 enters the FRAXA Drug Validation Initiative (FRAXA-DVI) for Fragile X mouse-model testing, generating data to guide development decisions.

Read More »
Neuronal synapse illustration showing neurotransmitter release, symbolizing how BK channel openers restore balance in Fragile X syndrome.

BK Channel Openers: From FRAXA Seed Funding to Big Pharma Investment and Trials

September 11, 2025

See how FRAXA’s early grants propelled Fragile X research from lab discoveries to industry momentum, with partners advancing therapies into trials.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (40)